USANA Health Sciences (NYSE:USNA) Upgraded by DA Davidson to Hold Rating
DA Davidson upgraded USANA Health Sciences (NYSE:USNA) to a "hold" rating. The stock traded down 3.8% on Friday, reaching $0.38. USANA's 12-month low is $0.28, and its high is $0.81. The company reported an EPS of $0.56, exceeding estimates. Insider trading included a sale of 675 shares by Director Gilbert A. Fuller. Hedge funds hold 54.25% of the stock. USANA develops and sells nutritional and personal care products globally.
USANA Health Sciences (NYSE:USNA - Get Free Report) was upgraded by research analysts at DA Davidson to a "hold" rating in a report issued on Friday,Zacks.com reports.
Get USANA Health Sciences alerts:
Separately, StockNews.com upgraded shares of USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research note on Thursday.
Get Our Latest Stock Report on USNA
USANA Health Sciences Trading Down 3.8 %
Shares of USNA traded down $1.33 during trading hours on Friday, reaching $33.38. 619,779 shares of the company traded hands, compared to its average volume of 84,047. The stock's fifty day moving average price is $37.96 and its 200 day moving average price is $40.47. USANA Health Sciences has a 12-month low of $33.28 and a 12-month high of $54.81. The firm has a market cap of $636.22 million, a price-to-earnings ratio of 11.80, a PEG ratio of 1.25 and a beta of 0.89.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. During the same period last year, the business posted $0.59 EPS. On average, research analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.
Insider Buying and Selling
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.33% of the company's stock.
Institutional Trading of USANA Health Sciences
A number of hedge funds have recently added to or reduced their stakes in USNA. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences during the third quarter worth approximately $30,000. KBC Group NV grew its stake in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company's stock valued at $40,000 after acquiring an additional 519 shares during the period. Centiva Capital LP purchased a new stake in USANA Health Sciences in the 3rd quarter worth $213,000. BOKF NA lifted its holdings in USANA Health Sciences by 99.4% during the second quarter. BOKF NA now owns 5,526 shares of the company's stock valued at $250,000 after purchasing an additional 2,755 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of USANA Health Sciences in the third quarter valued at about $250,000. 54.25% of the stock is owned by hedge funds and other institutional investors.
USANA Health Sciences Company Profile
(Get Free Report)USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
- Five stocks we like better than USANA Health Sciences
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- How to Invest in Biotech Stocks
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Biggest Stock Losers - Today’s Biggest Percentage Decliners
- MarketBeat Week in Review – 12/16 - 12/20
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad)
Should you invest $1,000 in USANA Health Sciences right now?
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here